DeFloria's Advancements in Cannabinoid Medicine Following Executive Order Lift DeFloria Inc. celebrates a pivotal moment in cannabinoid medicine with the reclassification of cannabis, propelling the development of important drugs for autism-related conditions.

DeFloria's Advancements in Cannabinoid Medicine Following Executive Order Lift #USA #Louisville #DeFloria #Charlotte's_Web #cannabinoid

DeFloria's AJA001 Gains FDA Approval for Phase II Trial Targeting Autism Spectrum Disorder DeFloria's AJA001, an oral cannabinoid drug for Autism Spectrum Disorder, has received FDA clearance for Phase 2 trials, aiming to address treatment gaps.

DeFloria's AJA001 Gains FDA Approval for Phase II Trial Targeting Autism Spectrum Disorder #United_States #Autism #Littleton #DeFloria #AJA001

DeFloria Unveils Promising Phase 1 Results for AJA001 in Autism Treatment DeFloria's Phase 1 trial results for AJA001 show safety and efficacy for autism spectrum disorder treatment, paving the way for future studies.

DeFloria Unveils Promising Phase 1 Results for AJA001 in Autism Treatment #United_States #DeFloria #AJA001 #Autism_Spectrum_Disorder #Littleton,_Colorado